Xbrane Biopharma AB (XBRANE) NPV

Sell:0.16 SEKBuy:0.16 SEK0.01 SEK (3.36%)

Prices delayed by at least 15 minutes
Sell:0.16 SEK
Buy:0.16 SEK
Change:0.01 SEK (3.36%)
Prices delayed by at least 15 minutes
Sell:0.16 SEK
Buy:0.16 SEK
Change:0.01 SEK (3.36%)
Prices delayed by at least 15 minutes

Company Information

About this company

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Key people

Martin Amark
Chief Executive Officer
Siavash Bashiri
Deputy Chief Executive Officer, Head - Biosimilars
Jane Benyami
Interim Chief Financial Officer
David Vikstroem
Chief Technology Officer
Maria Edebrink
Head - Regulatory Affairs and Quality Assurance
Xiaoli Hu
Head - Business Development
Nina Ivers
Head - Human Resource
Dina Jurman
Head - Clinical Affairs
Anders Wallstroem
Head - Manufacturing and Supply Chain
Anders Tullgren
Independent Chairman of the Board
Ivan Cohen - Tangui
Independent Director
Peter Edman
Independent Director
Kirsti Gjellan
Independent Director
Eva Nilsagard
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0007789409
  • Market cap
    SEK 237.18m
  • Employees
    65
  • Shares in issue
    1.53bn
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.